linjc16/ctgov huggingface dataset:
Retinal Venous Pressure (RVP) in Normals

Study Overview
=================
Brief Summary
-----------------
Determinate the standard values of the retinal venous pressure in a cohort of healthy subjects.

Detailed Description
-----------------
The retinal venous pressure (RVP) is an increasingly important dimension in the clinical assessment of retinal blood flow. In literature only very few and also divergent data on the retinal venous pressure in healthy volunteers are described. A normal value study will provide us with an up-to-date database.

Official Title
-----------------
Retinal Venous Pressure (RVP) in Normals

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy Exclusion Criteria: eye diseases systemic diseases term medication (except contraceptives) pregnancy allergies to the ingredients Alcaine, Tropicamide and Phenylephrine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal venous pressure | Quantification of the retinal venous pressure as a standard value in a cohort of healthy volunteers | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retinal venous pressure
The Role of Hydration on Exercise Performance - ODIN

Study Overview
=================
Brief Summary
-----------------
During exercise in the heat, there is a need to replenish fluids in order to avoid dehydration and decrease the risk for heat illness. What drives this urge to drink is the thirst mechanism. Following ingestion of fluids, there is an inhibition of thirst before there is a replenishing of fluids. However, there is little scientific evidence of where thirst is inhibited, if this thirst inhibition is augmented by exercise and how thirst itself influence exercise performance. Further, during rehydration studies, it is very difficult to successfully blind a subject to their drinking/hydration protocol. Previous studies that have blinded a subject to their drinking have used various methods such as intravenous fluid administration and/or nasogastric tubes. Therefore, the purpose of this research is to examine the mechanistic roles thirst inhibition plays while exercising in the heat while undergoing intravenous fluid administration. Specific attention will be directed to the cardiovascular and thermoregulatory function of the individuals. All blood, cardiovascular, thermoregulatory, and perceptual measures are shown in the diagram below.

Official Title
-----------------
The Role of Hydration on Exercise Performance - ODIN

Conditions
-----------------
Dehydration

Intervention / Treatment
-----------------
* Other: iv fluid infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cycling Racing History category 3 or higher USA cycling certification maximal oxygen uptake >55 ml/kg/min Exclusion Criteria: History of heat stroke Renal, cardiovascular, metabolic diseases Regular medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Euhydration - no thirst<br> | Other: iv fluid infusion<br>* Intravenous isotonic saline infusion<br>|
| Experimental: Dehydration - no Thirst<br> | Other: iv fluid infusion<br>* Intravenous isotonic saline infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5km - Cycling Time Trial | Time to completion 5 km cycling time trial in the heat | 2hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rectal Temperature | Body core temperature at the end of the 5 km time trial | 2hour |
Risk Factors for Nausea and Vomiting After Cesarean

Study Overview
=================
Brief Summary
-----------------
Investigators will observe the incidence of post-cesarean nausea or vomiting and try to associate it with some risk factors.

Detailed Description
-----------------
A single prospective cohort of women submitted to cesarean section who received spinal anesthesia will be assessed for the proposed risk factors and the incidence of nausea or vomiting will be observed during the first 48 hours.

Official Title
-----------------
Risk Factors for Nausea and Vomiting After Cesarean: Observational Prospective Study

Conditions
-----------------
Postoperative Nausea and Vomiting

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cesarean section indicated Spinal anesthesia indicated Exclusion Criteria: Cesarean section did not occur Spinal anesthesia was not provided Another spinal technique was added to spinal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Modeling<br>It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting. | |
| Validation<br>It is the cohort that will be used for validation of risk factors and models selected in the modeling group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Nausea or vomiting | The occurrence of postoperative nausea or vomiting, reported by the patient or witnessed by a healthcare provider during the first 48 hours after the cesarean. It is a dichotomic (true or false) outcome. | 48 hours. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative Nausea and Vomiting, cesarean, risk factors
Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
The use of steroids after kidney transplantation has been challenged because of variable adverse effects which may increase the patient morbidity and mortality. The aim of this study was to compare the safety and efficacy of immunosuppressive regimens consisting of cyclosporine (CsA) and mycophenolate mofetil (MMF) or tacrolimus (TAC) and MMF after steroid withdrawal 6 months after kidney transplantation in low-risk patients.

Detailed Description
-----------------
131 patients were randomized to CsA (n = 63) or TAC (n = 68). Of 118 patients who did not have a biopsy-proven rejection episode and who had a serum creatinine level < 2.0 mg/dL 6 months after transplantation, 55 were of the CsA group and 63 were of the TAC group. We assessed patient and graft survival, acute rejection episodes, and adverse events 5 years after transplantation.

Official Title
-----------------
Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation

Conditions
-----------------
Kidney Transplantation, Living Donors

Intervention / Treatment
-----------------
* Drug: tacrolimus
* Drug: cyclosporine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 15 years first living donor kidney transplantation Exclusion Criteria: congestive heart failure (ejection fraction < 35%) chronic liver disease underlying diabetes mellitus evidence of systemic infection at screening time history of malignant disease multiple organ transplantation positive serologic evidence of human immunodeficiency virus

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: cyclosporine<br> | Drug: cyclosporine<br> <br> |
| Experimental: Tacrolimus<br> | Drug: tacrolimus<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graft survival |  | 5 years | 
| Patient survival |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cumulative incidence of acute rejection |  | 5 years | 
| estimated glomerular filtration rate |  | 5 year | 
| new-onset diabetes mellitus |  | 5 year | 
| Hypertension |  | 5 year | 
| hyperlipidemia |  | 5 year |
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.

Detailed Description
-----------------
A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 10-6-10minutes.

Official Title
-----------------
Evaluating the Safety and Efficacy of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma

Conditions
-----------------
Liver Neoplasms

Intervention / Treatment
-----------------
* Procedure: Targeted Cryoablation Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of liver cancer based on histology or the current accepted radiological measures. Single Tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm. Life expectancy: Greater than 3 months. Patients' liver function is Child-pugh A or B. Ability to understand the study protocol and a willingness to sign a written informed consent document. Unable to receive operative surgery. Exclusion Criteria: Patients with other primary tumor except liver cancer. History of coagulation disorders or anemia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Targeted Cryoablation Therapy<br>liver cancer patients received targeted cryoablation therapy. | Procedure: Targeted Cryoablation Therapy<br>* A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of complete tumor ablation |  | Up to 4 weeks post surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events |  | Up to 4 weeks post surgery |
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.

Official Title
-----------------
An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

Conditions
-----------------
HIV Infections, Peripheral Nervous System Diseases, Pain

Intervention / Treatment
-----------------
* Drug: Capsaicin Dermal Patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Eligibility Criteria: Must have had HIV-associated neuropathy for at least 2 months, with moderate to severe pain in both feet. Must not have significant pain in feet due to other causes (for example, arthritis). Must have intact skin at the treatment area. Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks). Must not use topical pain medications for HIV-associated neuropathy. Must be able to comply with study requirements such as completing daily pain diary and attending study visits. Must be at least 18 years old, not pregnant, and be able to take care of self independently, with only occasional assistance if needed. No significant medical problems of the heart, kidneys, liver or lungs, or cancer. No history or current problem with substance abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Capsaicin Dermal Patch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dermal assessment, Pain measurement, Diary, Neuropathy, Analgesics/*therapeutic use, Capsaicin/*administration & dosage/adverse effects, HIV Infections/*complications/*drug therapy, Pain, Complementary Therapies
Familial Myeloproliferative Disorders

Study Overview
=================
Brief Summary
-----------------
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.

Official Title
-----------------
Molecular Biology of Familial Myeloproliferative Disorders

Conditions
-----------------
Polycythemia Vera, Essential Thrombocythemia, Idiopathic Myelofibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML). Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN). Participating subjects must be 7 years of age or older A written assent, parental permission or consent must be obtained prior to any study procedures being performed. Exclusion Criteria: Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, family clusters
FiO2 in Chronic Obstructive Pulmonary Disease (COPD) Patient Normobaric O2 Versus NIV

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare pharyngeal FiO2 in day time with nasal normobaric O2 with inhaled FiO2 in the night time with home care ventilator NIV at the same O2 flow.

Detailed Description
-----------------
in a prospective observational study the investigators will register FiO2 in 15 voluntaries COPD patients as following: Pharyngeal FiO2 (G5® Philips™ side stream FiO2) with O2 supply through nasal cannula at basal flow (flow needed by patient). In order to compare FiO2s the investigators will measure FiO2 with 150%, 75%, 50% and 25 % of basal Flow And FiO2 during nocturnal NIV (pressure support ventilation; Vivo 50®, Bréas™), using facial or nasal masque (Confort Gel® Respironics™). O2 flow will be basal flow.

Official Title
-----------------
Measured FiO2 With Nasal Canula O2 Versus Noninvasive Ventilation (NIV) With the Same O2 Flow, in COPD Patients the NIV LEAKS Study

Conditions
-----------------
COPD, Home Care, Oxygen Therapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent Exclusion Criteria: acute on chronic respiratory distress

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in FiO2 measured during NIV compared to the FiO2 measured during day time with nasal canula at similar O2 flow |  | 18 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time spent below different O2 levels during NIV despite constant O2 flow and their correlation to day time FiO2 with nasal canula |  | 18 hours | 
| levels of O2 adjustment needed to keep FiO2 stable with NIV |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Home ventilator, FiO2, O2, NIV, COPD
Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage

Study Overview
=================
Brief Summary
-----------------
Patients undergoing major surgery, trauma or burns are prone to develop an exacerbated inflammatory response, which is potentially lethal to the individual. Recently, the researchers' group showed in a rodent model of hemorrhagic shock that high-fat feeding administered before shock attenuates inflammation and reduces intestinal and hepatic damage. In the mechanism that underlies this protective effect, the release of cholecystokinin in gut wall and activation of efferent vagus bundles are crucial events. Before investigating the effect of high-fat nutrition in clinical setting, suitable markers of inflammation and organ damage need to be selected. In this study, blood will be collected in patients undergoing different types of operations. Consequently several markers for inflammation and organ damage will be determined. Hence, suitable parameters for a future high-fat intervention study will be selected.

Official Title
-----------------
Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage

Conditions
-----------------
Systemic Inflammatory Response Syndrome, Sepsis

Intervention / Treatment
-----------------
* Procedure: Blood collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years elective liver / colon / femur surgery Exclusion Criteria: Acute inflammation Chronic Obstructive Respiratory Disease Recent history of abdominal pain or diarrhea BMI < 18.5 Alcohol or Drugs abuses Recent intake of antibiotics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| I<br>Liver surgery | Procedure: Blood collection<br>* In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation<br>|
| II<br>Colon surgery | Procedure: Blood collection<br>* In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation<br>|
| III<br>Femur Fracture | Procedure: Blood collection<br>* In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SIRS, sepsis and related syndromes